7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,592.03

+550.64

+0.71%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

Aligos Therapeutics, Inc. (ALGS)

4.8000 -0.2300 (-4.57%)

At close: October 30 at 4:00:02 PM EDT

Loading Chart for ALGS

Chart Range Bar

Interval:

In partnership with ChartIQ

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates

Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos and Xiamen Amoytop sign deal for HBV therapy

Aligos and Xiamen Amoytop sign deal for HBV therapy

Mobilize your Website

View Site in Mobile | Classic

Share by: